Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial Article Swipe
T. Pascual
,
Guillermo Villacampa
,
Mafalda Oliveira
,
Santiago Escrivá-de-Romaní
,
Sònia Pernas
,
Laia Paré
,
Bárbara Adamo
,
Eduardo Martínez de Dueñas
,
J. Cortés
,
Antonia Perelló
,
Miguel Á. Galán
,
Mireia Melé
,
Lorea Villanueva
,
María González‐Rodríguez
,
Pablo Tolosa
,
Blanca González‐Farré
,
P. Galván
,
Jordi Canes
,
Paolo Nucíforo
,
J.M. Ferrero-Cafiero
,
Xavier González
,
Patricia Villagrasa
,
Aleix Prat
,
E. Ciruelos
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2025.105572
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2025.105572
These findings highlight the relevance of gene expression profiling in HER2-positive breast cancer and support biomarker-driven patient selection. Long-term PATRICIA results validate the potential of non-chemotherapy-based approaches in HR-positive/HER2-positive MBC.
Related Topics
Concepts
Trastuzumab
Palbociclib
Medicine
Oncology
Cohort
Metastatic breast cancer
Internal medicine
Breast cancer
Cancer
Overall survival
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.esmoop.2025.105572
- OA Status
- gold
- References
- 14
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4413881437
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4413881437Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.esmoop.2025.105572Digital Object Identifier
- Title
-
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trialWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-01Full publication date if available
- Authors
-
T. Pascual, Guillermo Villacampa, Mafalda Oliveira, Santiago Escrivá-de-Romaní, Sònia Pernas, Laia Paré, Bárbara Adamo, Eduardo Martínez de Dueñas, J. Cortés, Antonia Perelló, Miguel Á. Galán, Mireia Melé, Lorea Villanueva, María González‐Rodríguez, Pablo Tolosa, Blanca González‐Farré, P. Galván, Jordi Canes, Paolo Nucíforo, J.M. Ferrero-Cafiero, Xavier González, Patricia Villagrasa, Aleix Prat, E. CiruelosList of authors in order
- Landing page
-
https://doi.org/10.1016/j.esmoop.2025.105572Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.esmoop.2025.105572Direct OA link when available
- Concepts
-
Trastuzumab, Palbociclib, Medicine, Oncology, Cohort, Metastatic breast cancer, Internal medicine, Breast cancer, Cancer, Overall survivalTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
14Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4413881437 |
|---|---|
| doi | https://doi.org/10.1016/j.esmoop.2025.105572 |
| ids.doi | https://doi.org/10.1016/j.esmoop.2025.105572 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40896880 |
| ids.openalex | https://openalex.org/W4413881437 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D001943 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Breast Neoplasms |
| mesh[2].qualifier_ui | Q000401 |
| mesh[2].descriptor_ui | D001943 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | mortality |
| mesh[2].descriptor_name | Breast Neoplasms |
| mesh[3].qualifier_ui | Q000473 |
| mesh[3].descriptor_ui | D001943 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | pathology |
| mesh[3].descriptor_name | Breast Neoplasms |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D005260 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Female |
| mesh[5].qualifier_ui | Q000627 |
| mesh[5].descriptor_ui | D000068878 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | therapeutic use |
| mesh[5].descriptor_name | Trastuzumab |
| mesh[6].qualifier_ui | Q000008 |
| mesh[6].descriptor_ui | D000068878 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | administration & dosage |
| mesh[6].descriptor_name | Trastuzumab |
| mesh[7].qualifier_ui | Q000494 |
| mesh[7].descriptor_ui | D000068878 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | pharmacology |
| mesh[7].descriptor_name | Trastuzumab |
| mesh[8].qualifier_ui | Q000378 |
| mesh[8].descriptor_ui | D018719 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | metabolism |
| mesh[8].descriptor_name | Receptor, ErbB-2 |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D010879 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Piperazines |
| mesh[10].qualifier_ui | Q000008 |
| mesh[10].descriptor_ui | D010879 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | administration & dosage |
| mesh[10].descriptor_name | Piperazines |
| mesh[11].qualifier_ui | Q000494 |
| mesh[11].descriptor_ui | D010879 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | pharmacology |
| mesh[11].descriptor_name | Piperazines |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D008875 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Middle Aged |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000368 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Aged |
| mesh[14].qualifier_ui | Q000627 |
| mesh[14].descriptor_ui | D011725 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | therapeutic use |
| mesh[14].descriptor_name | Pyridines |
| mesh[15].qualifier_ui | Q000008 |
| mesh[15].descriptor_ui | D011725 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | administration & dosage |
| mesh[15].descriptor_name | Pyridines |
| mesh[16].qualifier_ui | Q000494 |
| mesh[16].descriptor_ui | D011725 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | pharmacology |
| mesh[16].descriptor_name | Pyridines |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000328 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Adult |
| mesh[18].qualifier_ui | Q000627 |
| mesh[18].descriptor_ui | D000971 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | therapeutic use |
| mesh[18].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D009362 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Neoplasm Metastasis |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D014408 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Biomarkers, Tumor |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D006801 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Humans |
| mesh[22].qualifier_ui | Q000188 |
| mesh[22].descriptor_ui | D001943 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | drug therapy |
| mesh[22].descriptor_name | Breast Neoplasms |
| mesh[23].qualifier_ui | Q000401 |
| mesh[23].descriptor_ui | D001943 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | mortality |
| mesh[23].descriptor_name | Breast Neoplasms |
| mesh[24].qualifier_ui | Q000473 |
| mesh[24].descriptor_ui | D001943 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | pathology |
| mesh[24].descriptor_name | Breast Neoplasms |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D005260 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Female |
| mesh[26].qualifier_ui | Q000627 |
| mesh[26].descriptor_ui | D000068878 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | therapeutic use |
| mesh[26].descriptor_name | Trastuzumab |
| mesh[27].qualifier_ui | Q000008 |
| mesh[27].descriptor_ui | D000068878 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | administration & dosage |
| mesh[27].descriptor_name | Trastuzumab |
| mesh[28].qualifier_ui | Q000494 |
| mesh[28].descriptor_ui | D000068878 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | pharmacology |
| mesh[28].descriptor_name | Trastuzumab |
| mesh[29].qualifier_ui | Q000378 |
| mesh[29].descriptor_ui | D018719 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | metabolism |
| mesh[29].descriptor_name | Receptor, ErbB-2 |
| mesh[30].qualifier_ui | Q000627 |
| mesh[30].descriptor_ui | D010879 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | therapeutic use |
| mesh[30].descriptor_name | Piperazines |
| mesh[31].qualifier_ui | Q000008 |
| mesh[31].descriptor_ui | D010879 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | administration & dosage |
| mesh[31].descriptor_name | Piperazines |
| mesh[32].qualifier_ui | Q000494 |
| mesh[32].descriptor_ui | D010879 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | pharmacology |
| mesh[32].descriptor_name | Piperazines |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D008875 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Middle Aged |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D000368 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Aged |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D011725 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Pyridines |
| mesh[36].qualifier_ui | Q000008 |
| mesh[36].descriptor_ui | D011725 |
| mesh[36].is_major_topic | True |
| mesh[36].qualifier_name | administration & dosage |
| mesh[36].descriptor_name | Pyridines |
| mesh[37].qualifier_ui | Q000494 |
| mesh[37].descriptor_ui | D011725 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | pharmacology |
| mesh[37].descriptor_name | Pyridines |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D000328 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Adult |
| mesh[39].qualifier_ui | Q000627 |
| mesh[39].descriptor_ui | D000971 |
| mesh[39].is_major_topic | True |
| mesh[39].qualifier_name | therapeutic use |
| mesh[39].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D009362 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Neoplasm Metastasis |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D014408 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Biomarkers, Tumor |
| type | article |
| title | Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial |
| biblio.issue | 9 |
| biblio.volume | 10 |
| biblio.last_page | 105572 |
| biblio.first_page | 105572 |
| topics[0].id | https://openalex.org/T12829 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Advanced Breast Cancer Therapies |
| topics[1].id | https://openalex.org/T10755 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9958999752998352 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | HER2/EGFR in Cancer Research |
| topics[2].id | https://openalex.org/T10183 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9793000221252441 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Breast Cancer Treatment Studies |
| funders[0].id | https://openalex.org/F4320307765 |
| funders[0].ror | https://ror.org/01xdqrp08 |
| funders[0].display_name | Pfizer |
| is_xpac | False |
| apc_list.value | 2750 |
| apc_list.currency | EUR |
| apc_list.value_usd | 2965 |
| apc_paid.value | 2750 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 2965 |
| concepts[0].id | https://openalex.org/C2779786085 |
| concepts[0].level | 4 |
| concepts[0].score | 0.922095537185669 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q412616 |
| concepts[0].display_name | Trastuzumab |
| concepts[1].id | https://openalex.org/C2779744173 |
| concepts[1].level | 5 |
| concepts[1].score | 0.828499972820282 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q15269707 |
| concepts[1].display_name | Palbociclib |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7174412608146667 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.7090797424316406 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C72563966 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6429631114006042 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[4].display_name | Cohort |
| concepts[5].id | https://openalex.org/C2775930923 |
| concepts[5].level | 4 |
| concepts[5].score | 0.6244679689407349 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q12859063 |
| concepts[5].display_name | Metastatic breast cancer |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5676309466362 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C530470458 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4813854992389679 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[7].display_name | Breast cancer |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4595753848552704 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C3019894029 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4227929711341858 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q332823 |
| concepts[9].display_name | Overall survival |
| keywords[0].id | https://openalex.org/keywords/trastuzumab |
| keywords[0].score | 0.922095537185669 |
| keywords[0].display_name | Trastuzumab |
| keywords[1].id | https://openalex.org/keywords/palbociclib |
| keywords[1].score | 0.828499972820282 |
| keywords[1].display_name | Palbociclib |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7174412608146667 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.7090797424316406 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/cohort |
| keywords[4].score | 0.6429631114006042 |
| keywords[4].display_name | Cohort |
| keywords[5].id | https://openalex.org/keywords/metastatic-breast-cancer |
| keywords[5].score | 0.6244679689407349 |
| keywords[5].display_name | Metastatic breast cancer |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.5676309466362 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/breast-cancer |
| keywords[7].score | 0.4813854992389679 |
| keywords[7].display_name | Breast cancer |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.4595753848552704 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/overall-survival |
| keywords[9].score | 0.4227929711341858 |
| keywords[9].display_name | Overall survival |
| language | en |
| locations[0].id | doi:10.1016/j.esmoop.2025.105572 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210217024 |
| locations[0].source.issn | 2059-7029 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2059-7029 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | ESMO Open |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | ESMO Open |
| locations[0].landing_page_url | https://doi.org/10.1016/j.esmoop.2025.105572 |
| locations[1].id | pmid:40896880 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | ESMO open |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40896880 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5051788065 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | T. Pascual |
| authorships[0].countries | ES |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210115097, https://openalex.org/I4210160192, https://openalex.org/I71999127 |
| authorships[0].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medicine Department, University of Barcelona, Barcelona, Spain. |
| authorships[0].institutions[0].id | https://openalex.org/I4210160192 |
| authorships[0].institutions[0].ror | https://ror.org/054vayn55 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210160192, https://openalex.org/I4387153040 |
| authorships[0].institutions[0].country_code | ES |
| authorships[0].institutions[0].display_name | Consorci Institut D'Investigacions Biomediques August Pi I Sunyer |
| authorships[0].institutions[1].id | https://openalex.org/I4210115097 |
| authorships[0].institutions[1].ror | https://ror.org/02a2kzf50 |
| authorships[0].institutions[1].type | healthcare |
| authorships[0].institutions[1].lineage | https://openalex.org/I4210115097 |
| authorships[0].institutions[1].country_code | ES |
| authorships[0].institutions[1].display_name | Hospital Clínic de Barcelona |
| authorships[0].institutions[2].id | https://openalex.org/I71999127 |
| authorships[0].institutions[2].ror | https://ror.org/021018s57 |
| authorships[0].institutions[2].type | education |
| authorships[0].institutions[2].lineage | https://openalex.org/I71999127 |
| authorships[0].institutions[2].country_code | ES |
| authorships[0].institutions[2].display_name | Universitat de Barcelona |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | T. Pascual |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medicine Department, University of Barcelona, Barcelona, Spain. |
| authorships[1].author.id | https://openalex.org/A5028946644 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4868-6585 |
| authorships[1].author.display_name | Guillermo Villacampa |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4387155398 |
| authorships[1].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[1].institutions[0].id | https://openalex.org/I4387155398 |
| authorships[1].institutions[0].ror | https://ror.org/054xx3904 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4387153040, https://openalex.org/I4387155398 |
| authorships[1].institutions[0].country_code | |
| authorships[1].institutions[0].display_name | Vall d'Hebron Institute of Oncology |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | G. Villacampa |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[2].author.id | https://openalex.org/A5053983312 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-9152-8799 |
| authorships[2].author.display_name | Mafalda Oliveira |
| authorships[2].countries | ES |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210127641 |
| authorships[2].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[2].institutions[0].id | https://openalex.org/I4210127641 |
| authorships[2].institutions[0].ror | https://ror.org/03ba28x55 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210127641 |
| authorships[2].institutions[0].country_code | ES |
| authorships[2].institutions[0].display_name | Vall d'Hebron Hospital Universitari |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | M. Oliveira |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[3].author.id | https://openalex.org/A5075766981 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7816-7589 |
| authorships[3].author.display_name | Santiago Escrivá-de-Romaní |
| authorships[3].countries | ES |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210127641 |
| authorships[3].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[3].institutions[0].id | https://openalex.org/I4210127641 |
| authorships[3].institutions[0].ror | https://ror.org/03ba28x55 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210127641 |
| authorships[3].institutions[0].country_code | ES |
| authorships[3].institutions[0].display_name | Vall d'Hebron Hospital Universitari |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | S. Escrivá-de-Romaní |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[4].author.id | https://openalex.org/A5028384284 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-1485-5080 |
| authorships[4].author.display_name | Sònia Pernas |
| authorships[4].countries | ES |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210087039, https://openalex.org/I4210107147 |
| authorships[4].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Institut Catala d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. |
| authorships[4].institutions[0].id | https://openalex.org/I4210107147 |
| authorships[4].institutions[0].ror | https://ror.org/01j1eb875 |
| authorships[4].institutions[0].type | government |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210107147 |
| authorships[4].institutions[0].country_code | ES |
| authorships[4].institutions[0].display_name | Institut Català d'Oncologia |
| authorships[4].institutions[1].id | https://openalex.org/I4210087039 |
| authorships[4].institutions[1].ror | https://ror.org/0008xqs48 |
| authorships[4].institutions[1].type | facility |
| authorships[4].institutions[1].lineage | https://openalex.org/I157913058, https://openalex.org/I2802050225, https://openalex.org/I4210087039, https://openalex.org/I4210096656, https://openalex.org/I4210106543, https://openalex.org/I4210107147, https://openalex.org/I4210153292, https://openalex.org/I4387153040, https://openalex.org/I71999127 |
| authorships[4].institutions[1].country_code | ES |
| authorships[4].institutions[1].display_name | Institut d'Investigació Biomédica de Bellvitge |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | S. Pernas |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Institut Catala d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. |
| authorships[5].author.id | https://openalex.org/A5070297345 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4904-558X |
| authorships[5].author.display_name | Laia Paré |
| authorships[5].countries | ES |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210133410 |
| authorships[5].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. |
| authorships[5].institutions[0].id | https://openalex.org/I4210133410 |
| authorships[5].institutions[0].ror | https://ror.org/03xb7kp74 |
| authorships[5].institutions[0].type | nonprofit |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210133410 |
| authorships[5].institutions[0].country_code | ES |
| authorships[5].institutions[0].display_name | Solti |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | L. Paré |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. |
| authorships[6].author.id | https://openalex.org/A5006511628 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-7129-8156 |
| authorships[6].author.display_name | Bárbara Adamo |
| authorships[6].countries | ES |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210115097, https://openalex.org/I4210160192, https://openalex.org/I71999127 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. |
| authorships[6].institutions[0].id | https://openalex.org/I4210160192 |
| authorships[6].institutions[0].ror | https://ror.org/054vayn55 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210160192, https://openalex.org/I4387153040 |
| authorships[6].institutions[0].country_code | ES |
| authorships[6].institutions[0].display_name | Consorci Institut D'Investigacions Biomediques August Pi I Sunyer |
| authorships[6].institutions[1].id | https://openalex.org/I4210115097 |
| authorships[6].institutions[1].ror | https://ror.org/02a2kzf50 |
| authorships[6].institutions[1].type | healthcare |
| authorships[6].institutions[1].lineage | https://openalex.org/I4210115097 |
| authorships[6].institutions[1].country_code | ES |
| authorships[6].institutions[1].display_name | Hospital Clínic de Barcelona |
| authorships[6].institutions[2].id | https://openalex.org/I71999127 |
| authorships[6].institutions[2].ror | https://ror.org/021018s57 |
| authorships[6].institutions[2].type | education |
| authorships[6].institutions[2].lineage | https://openalex.org/I71999127 |
| authorships[6].institutions[2].country_code | ES |
| authorships[6].institutions[2].display_name | Universitat de Barcelona |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | B. Adamo |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. |
| authorships[7].author.id | https://openalex.org/A5075269446 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-0110-4816 |
| authorships[7].author.display_name | Eduardo Martínez de Dueñas |
| authorships[7].countries | ES |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210096764 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Castellón, Spain. |
| authorships[7].institutions[0].id | https://openalex.org/I4210096764 |
| authorships[7].institutions[0].ror | https://ror.org/00t7jb983 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210096764 |
| authorships[7].institutions[0].country_code | ES |
| authorships[7].institutions[0].display_name | Consorcio Hospitalario Provincial de Castellón |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | E. Martínez |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Medical Oncology, Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Castellón, Spain. |
| authorships[8].author.id | https://openalex.org/A5069079082 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | J. Cortés |
| authorships[8].affiliations[0].raw_affiliation_string | International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain. |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | J. Cortés |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain. |
| authorships[9].author.id | https://openalex.org/A5011090752 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-4137-8790 |
| authorships[9].author.display_name | Antonia Perelló |
| authorships[9].countries | ES |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210152826 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Hospital Son Espases, Palma, Spain. |
| authorships[9].institutions[0].id | https://openalex.org/I4210152826 |
| authorships[9].institutions[0].ror | https://ror.org/05jmd4043 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210152826 |
| authorships[9].institutions[0].country_code | ES |
| authorships[9].institutions[0].display_name | Hospital Universitario Son Espases |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | A. Perelló |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Medical Oncology, Hospital Son Espases, Palma, Spain. |
| authorships[10].author.id | https://openalex.org/A5102757819 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-6695-1509 |
| authorships[10].author.display_name | Miguel Á. Galán |
| authorships[10].countries | ES |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210087626 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Hospital Son Llàtzer, Palma, Spain. |
| authorships[10].institutions[0].id | https://openalex.org/I4210087626 |
| authorships[10].institutions[0].ror | https://ror.org/003ez4w63 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210087626 |
| authorships[10].institutions[0].country_code | ES |
| authorships[10].institutions[0].display_name | Hospital Son Llatzer |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | M. Galan |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Medical Oncology, Hospital Son Llàtzer, Palma, Spain. |
| authorships[11].author.id | https://openalex.org/A5077308675 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-3408-8018 |
| authorships[11].author.display_name | Mireia Melé |
| authorships[11].countries | ES |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210149100 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Hospital Sant Joan, Reus, Spain. |
| authorships[11].institutions[0].id | https://openalex.org/I4210149100 |
| authorships[11].institutions[0].ror | https://ror.org/04f7pyb58 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210149100 |
| authorships[11].institutions[0].country_code | ES |
| authorships[11].institutions[0].display_name | Hospital Universitari Sant Joan de Reus |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | M. Melé |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Medical Oncology, Hospital Sant Joan, Reus, Spain. |
| authorships[12].author.id | https://openalex.org/A5053324492 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-1858-7076 |
| authorships[12].author.display_name | Lorea Villanueva |
| authorships[12].countries | ES |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210133410 |
| authorships[12].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain. |
| authorships[12].institutions[0].id | https://openalex.org/I4210133410 |
| authorships[12].institutions[0].ror | https://ror.org/03xb7kp74 |
| authorships[12].institutions[0].type | nonprofit |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210133410 |
| authorships[12].institutions[0].country_code | ES |
| authorships[12].institutions[0].display_name | Solti |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | L. Villanueva |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain. |
| authorships[13].author.id | https://openalex.org/A5027232503 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-8878-2219 |
| authorships[13].author.display_name | María González‐Rodríguez |
| authorships[13].countries | ES |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210115097, https://openalex.org/I4210160192, https://openalex.org/I71999127 |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. |
| authorships[13].institutions[0].id | https://openalex.org/I4210160192 |
| authorships[13].institutions[0].ror | https://ror.org/054vayn55 |
| authorships[13].institutions[0].type | facility |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210160192, https://openalex.org/I4387153040 |
| authorships[13].institutions[0].country_code | ES |
| authorships[13].institutions[0].display_name | Consorci Institut D'Investigacions Biomediques August Pi I Sunyer |
| authorships[13].institutions[1].id | https://openalex.org/I4210115097 |
| authorships[13].institutions[1].ror | https://ror.org/02a2kzf50 |
| authorships[13].institutions[1].type | healthcare |
| authorships[13].institutions[1].lineage | https://openalex.org/I4210115097 |
| authorships[13].institutions[1].country_code | ES |
| authorships[13].institutions[1].display_name | Hospital Clínic de Barcelona |
| authorships[13].institutions[2].id | https://openalex.org/I71999127 |
| authorships[13].institutions[2].ror | https://ror.org/021018s57 |
| authorships[13].institutions[2].type | education |
| authorships[13].institutions[2].lineage | https://openalex.org/I71999127 |
| authorships[13].institutions[2].country_code | ES |
| authorships[13].institutions[2].display_name | Universitat de Barcelona |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | M. Gonzalez-Rodriguez |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. |
| authorships[14].author.id | https://openalex.org/A5008566812 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-3747-4766 |
| authorships[14].author.display_name | Pablo Tolosa |
| authorships[14].countries | ES |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210086614 |
| authorships[14].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. |
| authorships[14].institutions[0].id | https://openalex.org/I4210086614 |
| authorships[14].institutions[0].ror | https://ror.org/002x1sg85 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210086614 |
| authorships[14].institutions[0].country_code | ES |
| authorships[14].institutions[0].display_name | Research Institute Hospital 12 de Octubre |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | P. Tolosa |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. |
| authorships[15].author.id | https://openalex.org/A5042649658 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-1796-7248 |
| authorships[15].author.display_name | Blanca González‐Farré |
| authorships[15].countries | ES |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210115097 |
| authorships[15].affiliations[0].raw_affiliation_string | Department of Pathology, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, Barcelona, Spain. |
| authorships[15].institutions[0].id | https://openalex.org/I4210115097 |
| authorships[15].institutions[0].ror | https://ror.org/02a2kzf50 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210115097 |
| authorships[15].institutions[0].country_code | ES |
| authorships[15].institutions[0].display_name | Hospital Clínic de Barcelona |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | B. González-Farré |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Department of Pathology, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, Barcelona, Spain. |
| authorships[16].author.id | https://openalex.org/A5109717501 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | P. Galván |
| authorships[16].countries | ES |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210160192 |
| authorships[16].affiliations[0].raw_affiliation_string | Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. |
| authorships[16].institutions[0].id | https://openalex.org/I4210160192 |
| authorships[16].institutions[0].ror | https://ror.org/054vayn55 |
| authorships[16].institutions[0].type | facility |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210160192, https://openalex.org/I4387153040 |
| authorships[16].institutions[0].country_code | ES |
| authorships[16].institutions[0].display_name | Consorci Institut D'Investigacions Biomediques August Pi I Sunyer |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | P. Galván |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. |
| authorships[17].author.id | https://openalex.org/A5051034956 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-1309-5745 |
| authorships[17].author.display_name | Jordi Canes |
| authorships[17].countries | ES |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210133410 |
| authorships[17].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain. |
| authorships[17].institutions[0].id | https://openalex.org/I4210133410 |
| authorships[17].institutions[0].ror | https://ror.org/03xb7kp74 |
| authorships[17].institutions[0].type | nonprofit |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210133410 |
| authorships[17].institutions[0].country_code | ES |
| authorships[17].institutions[0].display_name | Solti |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | J. Canes |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain. |
| authorships[18].author.id | https://openalex.org/A5081259888 |
| authorships[18].author.orcid | https://orcid.org/0000-0003-1380-0990 |
| authorships[18].author.display_name | Paolo Nucíforo |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4387155398 |
| authorships[18].affiliations[0].raw_affiliation_string | Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[18].institutions[0].id | https://openalex.org/I4387155398 |
| authorships[18].institutions[0].ror | https://ror.org/054xx3904 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I4387153040, https://openalex.org/I4387155398 |
| authorships[18].institutions[0].country_code | |
| authorships[18].institutions[0].display_name | Vall d'Hebron Institute of Oncology |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | P. Nuciforo |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| authorships[19].author.id | https://openalex.org/A5032305758 |
| authorships[19].author.orcid | https://orcid.org/0000-0001-8796-8812 |
| authorships[19].author.display_name | J.M. Ferrero-Cafiero |
| authorships[19].countries | ES |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I4210133410 |
| authorships[19].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain. |
| authorships[19].institutions[0].id | https://openalex.org/I4210133410 |
| authorships[19].institutions[0].ror | https://ror.org/03xb7kp74 |
| authorships[19].institutions[0].type | nonprofit |
| authorships[19].institutions[0].lineage | https://openalex.org/I4210133410 |
| authorships[19].institutions[0].country_code | ES |
| authorships[19].institutions[0].display_name | Solti |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | J.M. Ferrero-Cafiero |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain. |
| authorships[20].author.id | https://openalex.org/A5025842545 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-5797-7037 |
| authorships[20].author.display_name | Xavier González |
| authorships[20].countries | ES |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I4210119948 |
| authorships[20].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Institut Oncològic Dr. Rosell, Barcelona, Spain; Hospital General de Catalunya, Sant Cugat del Vallès, Barcelona, Spain; Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain. |
| authorships[20].institutions[0].id | https://openalex.org/I4210119948 |
| authorships[20].institutions[0].ror | https://ror.org/02k4qm934 |
| authorships[20].institutions[0].type | healthcare |
| authorships[20].institutions[0].lineage | https://openalex.org/I4210119948 |
| authorships[20].institutions[0].country_code | ES |
| authorships[20].institutions[0].display_name | Hospital General de Catalunya |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | X. González-Farré |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Institut Oncològic Dr. Rosell, Barcelona, Spain; Hospital General de Catalunya, Sant Cugat del Vallès, Barcelona, Spain; Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain. |
| authorships[21].author.id | https://openalex.org/A5080122151 |
| authorships[21].author.orcid | https://orcid.org/0000-0002-8662-3641 |
| authorships[21].author.display_name | Patricia Villagrasa |
| authorships[21].countries | ES |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I4210133410 |
| authorships[21].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. |
| authorships[21].institutions[0].id | https://openalex.org/I4210133410 |
| authorships[21].institutions[0].ror | https://ror.org/03xb7kp74 |
| authorships[21].institutions[0].type | nonprofit |
| authorships[21].institutions[0].lineage | https://openalex.org/I4210133410 |
| authorships[21].institutions[0].country_code | ES |
| authorships[21].institutions[0].display_name | Solti |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | P. Villagrasa |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. |
| authorships[22].author.id | https://openalex.org/A5089513581 |
| authorships[22].author.orcid | https://orcid.org/0000-0003-2377-540X |
| authorships[22].author.display_name | Aleix Prat |
| authorships[22].countries | ES |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I4210115097, https://openalex.org/I4210160192, https://openalex.org/I71999127 |
| authorships[22].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medicine Department, University of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain. Electronic address: [email protected]. |
| authorships[22].institutions[0].id | https://openalex.org/I4210160192 |
| authorships[22].institutions[0].ror | https://ror.org/054vayn55 |
| authorships[22].institutions[0].type | facility |
| authorships[22].institutions[0].lineage | https://openalex.org/I4210160192, https://openalex.org/I4387153040 |
| authorships[22].institutions[0].country_code | ES |
| authorships[22].institutions[0].display_name | Consorci Institut D'Investigacions Biomediques August Pi I Sunyer |
| authorships[22].institutions[1].id | https://openalex.org/I4210115097 |
| authorships[22].institutions[1].ror | https://ror.org/02a2kzf50 |
| authorships[22].institutions[1].type | healthcare |
| authorships[22].institutions[1].lineage | https://openalex.org/I4210115097 |
| authorships[22].institutions[1].country_code | ES |
| authorships[22].institutions[1].display_name | Hospital Clínic de Barcelona |
| authorships[22].institutions[2].id | https://openalex.org/I71999127 |
| authorships[22].institutions[2].ror | https://ror.org/021018s57 |
| authorships[22].institutions[2].type | education |
| authorships[22].institutions[2].lineage | https://openalex.org/I71999127 |
| authorships[22].institutions[2].country_code | ES |
| authorships[22].institutions[2].display_name | Universitat de Barcelona |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | A. Prat |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medicine Department, University of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain. Electronic address: [email protected]. |
| authorships[23].author.id | https://openalex.org/A5083819623 |
| authorships[23].author.orcid | |
| authorships[23].author.display_name | E. Ciruelos |
| authorships[23].countries | ES |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I4210086614, https://openalex.org/I4210122338 |
| authorships[23].affiliations[0].raw_affiliation_string | SOLTI Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Medical Oncology Department, HM Hospitales, Madrid, Spain. Electronic address: [email protected]. |
| authorships[23].institutions[0].id | https://openalex.org/I4210122338 |
| authorships[23].institutions[0].ror | https://ror.org/01ynvwr63 |
| authorships[23].institutions[0].type | healthcare |
| authorships[23].institutions[0].lineage | https://openalex.org/I4210122338 |
| authorships[23].institutions[0].country_code | ES |
| authorships[23].institutions[0].display_name | HM Hospitales |
| authorships[23].institutions[1].id | https://openalex.org/I4210086614 |
| authorships[23].institutions[1].ror | https://ror.org/002x1sg85 |
| authorships[23].institutions[1].type | healthcare |
| authorships[23].institutions[1].lineage | https://openalex.org/I4210086614 |
| authorships[23].institutions[1].country_code | ES |
| authorships[23].institutions[1].display_name | Research Institute Hospital 12 de Octubre |
| authorships[23].author_position | last |
| authorships[23].raw_author_name | E. Ciruelos |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | SOLTI Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Medical Oncology Department, HM Hospitales, Madrid, Spain. Electronic address: [email protected]. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.esmoop.2025.105572 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12829 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Advanced Breast Cancer Therapies |
| related_works | https://openalex.org/W3161515104, https://openalex.org/W3203106735, https://openalex.org/W4253790588, https://openalex.org/W4403717144, https://openalex.org/W3203690439, https://openalex.org/W2042663917, https://openalex.org/W3092326212, https://openalex.org/W2480965698, https://openalex.org/W4206711305, https://openalex.org/W4283528480 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.esmoop.2025.105572 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210217024 |
| best_oa_location.source.issn | 2059-7029 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2059-7029 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | ESMO Open |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | ESMO Open |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.esmoop.2025.105572 |
| primary_location.id | doi:10.1016/j.esmoop.2025.105572 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210217024 |
| primary_location.source.issn | 2059-7029 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2059-7029 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | ESMO Open |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | ESMO Open |
| primary_location.landing_page_url | https://doi.org/10.1016/j.esmoop.2025.105572 |
| publication_date | 2025-09-01 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3012380787, https://openalex.org/W4200453601, https://openalex.org/W4311116389, https://openalex.org/W4402514733, https://openalex.org/W4388040922, https://openalex.org/W3020482066, https://openalex.org/W3087683013, https://openalex.org/W4399150586, https://openalex.org/W4405926264, https://openalex.org/W2132619562, https://openalex.org/W2161109798, https://openalex.org/W2559059115, https://openalex.org/W3131686998, https://openalex.org/W2947157601 |
| referenced_works_count | 14 |
| abstract_inverted_index.in | 9, 27 |
| abstract_inverted_index.of | 5, 24 |
| abstract_inverted_index.and | 13 |
| abstract_inverted_index.the | 3, 22 |
| abstract_inverted_index.MBC. | 29 |
| abstract_inverted_index.gene | 6 |
| abstract_inverted_index.These | 0 |
| abstract_inverted_index.breast | 11 |
| abstract_inverted_index.cancer | 12 |
| abstract_inverted_index.patient | 16 |
| abstract_inverted_index.results | 20 |
| abstract_inverted_index.support | 14 |
| abstract_inverted_index.PATRICIA | 19 |
| abstract_inverted_index.findings | 1 |
| abstract_inverted_index.validate | 21 |
| abstract_inverted_index.Long-term | 18 |
| abstract_inverted_index.highlight | 2 |
| abstract_inverted_index.potential | 23 |
| abstract_inverted_index.profiling | 8 |
| abstract_inverted_index.relevance | 4 |
| abstract_inverted_index.approaches | 26 |
| abstract_inverted_index.expression | 7 |
| abstract_inverted_index.selection. | 17 |
| abstract_inverted_index.HER2-positive | 10 |
| abstract_inverted_index.biomarker-driven | 15 |
| abstract_inverted_index.non-chemotherapy-based | 25 |
| abstract_inverted_index.HR-positive/HER2-positive | 28 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 24 |
| citation_normalized_percentile.value | 0.53106173 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |